01—Abstract
Summary
Summary of the 10-K filed February 23, 2015. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation (IEX) reported 2014 net sales of $2.15 billiona, up 6% from $2.02 billion in 2013, with organic sales up 5%.
Operating income rose to $431.2 millionb (operating margin 20.1%), and net income increased 9% to $279.4 million. Diluted EPS was $3.45, up $0.36 from $3.09. Excluding $13.7 million of restructuring costs, adjusted operating income was $444.9 million and adjusted EPS was $3.57.
Management expects 2015 organic revenue growth of 1 to 2 percent and EPS of $3.65 to $3.75c, citing a soft European market and volatile Asia. The company operates three reportable segments: Fluid & Metering Technologies (42% of 2014 sales, 43% of operating income), Health & Science Technologies (35% of sales, 31% of operating income), and Fire & Safety/Diversified Products (23% of sales, 26% of operating income). Roughly 50% of 2014 sales were to customers outside the U.S. Cash from operations was $368.0 million, and capital expenditures were $48.0 million.
Total borrowings were $863.9 milliond, and the company repurchased 3.0 million shares for $222.5 million during 2014. Remaining repurchase authorization was $545 million at year-end. The filing also discloses goodwill of $1.32 billion and intangible assets of $271.2 million, which together make up a significant share of total assets of $2.91 billion.
Management noted that the IOP reporting unit had the thinnest headroom, with fair value greater than 15% above carrying value. The company is also a defendant in asbestos-related lawsuits, for which no provision has been made beyond insurance deductibles.
02—Key points
Key Highlights
- Net sales of $2,147.8 million in 2014, up 6% (5% organic), with operating income of $431.2 million, up 9%.
- Diluted EPS of $3.45 in 2014, up from $3.09; adjusted EPS of $3.57 excluding $13.7 million of restructuring costs.
- Fluid & Metering Technologies generated 42% of sales and 43% of operating income; Health & Science Technologies 35% and 31%; Fire & Safety/Diversified Products 23% and 26%.
- 2015 outlook: 1 to 2 percent organic revenue growth and EPS of $3.65 to $3.75, with a soft European market and volatile Asia.
- Cash flow from operations of $368.0 million and capital expenditures of $48.0 million in 2014; cash and equivalents of $509.1 million.
- Total borrowings of $863.9 million; net revolver availability of about $577.6 million; interest coverage of 12.72 to 1 versus a 3.0 minimum covenant.
- Repurchased 3.0 million shares for $222.5 million in 2014, with $545 million of authorization remaining; dividends increased to $1.12 per share from $0.89.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2014, Idex kept $0.13.
- Revenue$2.15B100.0%
- Cost of revenue−$1.20B55.8%
- Gross profit$949.3M44.2%
- Operating costs−$518.1M24.1%
- Operating income$431.2M20.1%
- Interest, other & tax−$151.8M7.1%
- Net income$279.4M13.0%
Where FY2014 revenue went
$2.15B- Cost of revenue: $1.20B, 56% of revenue
- SG&A: $504.4M, 23% of revenue
- Net income: $279.4M, 13% of revenue
- R&D: $36.8M, 1.7% of revenue
- Interest, other & tax: $151.8M, 7.1% of revenue
Kept 13% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 23, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $2.15B$2.02B | +6.1% |
| Cost of Revenue | $1.20B$1.15B | +4.1% |
| Gross Profit | $949.32M$873.36M | +8.7% |
| R&D Expenses | $36.80M$33.00M | +11.5% |
| SG&A Expenses | $504.42M$477.85M | +5.6% |
| Operating Income | $431.22M$395.51M | +9.0% |
| Interest Expense | $41.90M$42.21M | −0.7% |
| Net Income | $279.39M$255.22M | +9.5% |
| EPS (Basic) | $3.48$3.11 | +11.9% |
| EPS (Diluted) | $3.45$3.09 | +11.7% |
| Shares Outstanding (Basic) | 79.72M81.52M | −2.2% |
| Shares Outstanding (Diluted) | 80.73M82.49M | −2.1% |
05—Questions
Frequently Asked Questions
How did IDEX perform financially in 2014?
Net sales rose 6% to $2.15 billion, with organic sales up 5%. Operating income increased 9% to $431.2 million, and net income grew 9% to $279.4 million. Diluted EPS was $3.45, compared with $3.09 in 2013.
What is the company's outlook for 2015?
Management expects 1 to 2 percent organic revenue growth and EPS of $3.65 to $3.75. It anticipates solid North American demand, a soft European market throughout 2015, and volatile Asian markets.
How is the business organized?
IDEX has three reportable segments: Fluid & Metering Technologies, Health & Science Technologies, and Fire & Safety/Diversified Products. Fluid & Metering Technologies was the largest, at 42% of 2014 sales. Roughly 50% of total sales were to customers outside the U.S.
What are the main risks highlighted in the filing?
Key risks include economic conditions in the U.S. and abroad, international operating and currency exposure, competition, raw material availability, and the ability to complete and integrate acquisitions. Goodwill and intangible assets of $1.32 billion and $271.2 million are a significant share of total assets, so impairment would reduce net worth. The company also faces asbestos-related lawsuits, for which it has made no provision beyond insurance deductibles.
How is the company returning capital to shareholders?
In 2014 IDEX repurchased 3.0 million shares for $222.5 million and paid cash dividends of $1.12 per share, up from $0.89 in 2013. The Board increased the repurchase authorization by $400.0 million in November 2014, leaving $545 million available at year-end.
06—Continue